Measuring Fatty Acid Oxidation in Cerebral Metastases Using [18F]FPIA
A legfontosabb adatok
- Ki végzi
- Imperial College London
- Hol
- Egyesült Királyság1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 22 fő vett részt
- Kezdés
- 2020. szept. 25.
- Befejezés
- 2024. márc. 1.
- A vizsgálat típusa
- Megfigyeléses, 2 csoport
- A vizsgált kezelések
- [18F]FPIA PET/MRI
- A regiszteradat frissítve
- 2025. április 2.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter összes feltétele (15)A regiszter feltételeinek elrejtése
Ki vehet részt
- Treatment naïve; or
- SRS+/- combination treated - Patients that have completed the SRS part of a combination regime enabling a 4-8 week post-SRS treatment PET/MRI scan; and
- That fulfil the following criteria:
- Age ≥18
- Target metastases size ≥ 1cm
- WHO performance status 0 - 2
- If female, the subject is either post-menopausal (at least 1 year), or surgically sterilized (has had a documented bilateral oophorectomy and/or documented hysterectomy for at least 2 years), or if of childbearing potential, must have a negative urine beta human chorionic gonadotropin (beta-hCG) pregnancy test done prior to tracer administration
- The subject is able and willing to comply with study procedures, and signed and dated informed consent is obtained
- The subject has a satisfactory medical history as judged by the investigator with no significant co-morbidities
- The subject's clinical and laboratory tests are within normal limits and/or considered clinically insignificant
Ki nem vehet részt
- Prior use within 14 days of enrolment or concurrent therapy with any other investigational agent
- The subject has non-MRI compatible devices (e.g.a pacemaker, an implantable cardioverter-defibrillator (ICD), a nerve stimulator, a cochlear implant or a drug pump) or implanted material (e.g. non-MRI compatible sternal wires, biostimulators, metals or alloys)
- Any other chronic illness that will or musculoskeletal condition that would not allow comfortable performance of a PET study
- Unsatisfactory renal function (eGFR<30)
- The subject is pregnant or lactating
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Cerebral metastases represent a significant problem for oncological management. It is estimated that 20-40% of patients with cancer will develop metastatic cancer to the brain during the course of their illness. 18F-fluoropivalate ([18F]FPIA) is a new tracer that images short chain fatty acid (SCFA) uptake in tumours, a key component of fatty acid oxidation.
A teljes eredeti leírásKevesebb
The aim of this study is to quantify the degree of early step fatty acid oxidation in cerebral metastases as imaged by [18F]FPIA Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI).
The investigators hypothesise that FPIA uptake will be higher in metastases that are treatment naïve compared to those that have undergone treatment, in keeping with viable tumour cells having a high propensity to generate ATP and NADPH via fatty acid oxidation under bioenergetic stress.
A vizsgálat 2 csoportja
- Patients With Radiological Evidence of IMD That Are Treatment Naive.
Participants with radiological evidence of intracranial metastatic disease (IMD) on standard of care contrast-enhanced magnetic resonance imaging (CE-MRI) that were treatment-naive at the time of enrolment/\[18F\]FPIA PET-mpMRI scanning. Participants enrolled into the study had \[18F\]FPIA positron emission tomography-multiparametric magnetic resonance imaging (PET-mMRI) scan(s) performed at the Invicro, Centre for Imaging Sciences. A single intravenous dose of \[18F\]FPIA (maximum, 370MBq) was administered to the participant followed by a whole brain dynamic PET-MRI scan over 66 minutes.
Kezelés: [18F]FPIA PET/MRI
- Patients With Radiological Evidence of IMD That Had Completed Stereotactic Radiosurgery.
Participants with radiological evidence of intracranial metastatic disease (IMD) on standard of care contrast-enhanced magnetic resonance imaging (CE-MRI) that had completed stereotactic radiosurgery (SRS) (+/- combination therapy) within 4-8 weeks of \[18F\]FPIA PET-mMRI. Participants enrolled into the study had \[18F\]FPIA positron emission tomography-multiparametric magnetic resonance imaging (PET-mMRI) scans performed at the Invicro, Centre for Imaging Sciences. A single intravenous dose of \[18F\]FPIA (maximum, 370MBq) was administered to the participant followed by a whole brain dynamic PET-MRI scan over 66 minutes.
Kezelés: [18F]FPIA PET/MRI
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Determining the Magnitude of Early Steps of Fatty Acid Oxidation in Cerebral Metastases Using [18F]FPIA PET/MRI
- Publikációk
- A hybrid [18F]fluoropivalate PET-multiparametric MRI to detect and characterise brain tumour metastases based on a permissive environment for monocarboxylate transport.European journal of nuclear medicine and molecular imaging, 2025
- A regiszteradat frissítve
- 2025. április 2.